NVO - Novo Nordisk hemophilia candidate Mim8 meets primary goals in phase 3 trial
2024-05-13 14:28:09 ET
More on Novo Nordisk
- The FTC Cracks Down On Novo Nordisk's Ozempic
- Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation
- Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
- BoA raises 2024 Novo Nordisk Wegovy sales estimates on prescription trends
- U.S. dialysis volumes expected to rebound in 2024 despite GLP-1 impact